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The polymorphic variant rs1800734 
influences methylation acquisition 
and allele-specific TFAP4 binding 
in the MLH1 promoter leading to 
differential mRNA expression
Rachael thomas1, Davide trapani2, Lily Goodyer-Sait3, Marketa tomkova4,  
ceres fernandez-Rozadilla  5, nora Sahnane  2, connor Woolley  6, Hayley Davis7, 
Laura Chegwidden8, Skirmantas Kriaucionis4, timothy Maughan9, Simon Leedham7, 
claire palles8, Daniela Furlan  2, ian tomlinson  6 & Annabelle Lewis1,10
Expression of the mismatch repair gene MutL homolog 1 (MLH1) is silenced in a clinically important 
subgroup of sporadic colorectal cancers. These cancers exhibit hypermutability with microsatellite 
instability (MSI) and differ from microsatellite-stable (MSS) colorectal cancers in both prognosis and 
response to therapies. Loss of MLH1 is usually due to epigenetic silencing with associated promoter 
methylation; coding somatic mutations rarely occur. Here we use the presence of a colorectal cancer 
(CRC) risk variant (rs1800734) within the MLH1 promoter to investigate the poorly understood 
mechanisms of MLH1 promoter methylation and loss of expression. We confirm the association of 
rs1800734 with MSI+ but not MSS cancer risk in our own data and by meta-analysis. Using sensitive 
allele-specific detection methods, we demonstrate that MLH1 is the target gene for rs1800734 
mediated cancer risk. In normal colon tissue, small allele-specific differences exist only in MLH1 
promoter methylation, but not gene expression. In contrast, allele-specific differences in both MLH1 
methylation and expression are present in MSI+ cancers. We show that MLH1 transcriptional repression 
is dependent on DNA methylation and can be reversed by a methylation inhibitor. The rs1800734 allele 
influences the rate of methylation loss and amount of re-expression. The transcription factor TFAP4 
binds to the rs1800734 region but with much weaker binding to the risk than the protective allele. 
TFAP4 binding is absent on both alleles when promoter methylation is present. Thus we propose that 
TFAP4 binding shields the protective rs1800734 allele of the MLH1 promoter from BRAF induced DNA 
methylation more effectively than the risk allele.
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Colorectal cancer (CRC) is a major cause of morbidity and mortality, with a lifetime risk of ~6% in the UK. 
About 15% of sporadic CRCs are deficient in DNA mismatch repair (MMR), a process that normally acts to cor-
rect spontaneous DNA replication errors. MMR-deficient cancers exhibit a high rate of mutation genome-wide, 
but this is most evident at short repeat sequences, causing these cancers to be termed “microsatellite-unstable” 
(MSI+). The majority of sporadic MSI+ cancers have reduced protein and mRNA expression of the MMR 
gene, MutL homolog 1 (MLH1). This loss of MLH1 is rarely caused by mutations. Instead, epigenetic silencing 
occurs, with high levels of DNA methylation present in the MLH1 promoter. Understanding how MSI+ CRCs 
develop is clinically important. Stage II/III MSI+ CRCs have a relatively favourable prognosis, whereas stage IV 
MSI+ tumours have a poor prognosis. MSI+ CRCs respond poorly to commonly used chemotherapy, such as 
5-fluorouracil but are targetable by immune checkpoint inhibitors due to their high number of neoantigens1,2.
The importance of MLH1 in CRC and its propensity for hypermethylation have been known for some time3, 
and there is a substantial body of literature about the use of MLH1 methylation and/or MSI as a biomarker in the 
classification of CRC. However, the biological mechanisms underlying the methylation have not been investigated 
in detail until recently. Fang et al.4 have demonstrated in cancer cell lines that BRAF oncogenic mutations mediate 
the CpG island methylation phenotype (CIMP) resulting in hypermethylation at MLH1 and other CIMP marker 
genes, via the transcriptional repressor MAFG4.
Some further understanding of the acquisition of MLH1 promoter methylation has come from the study of 
a single nucleotide polymorphism (SNP), rs1800734, that lies in the 5′ untranslated region of MLH1. An asso-
ciation between rs1800734 and CRC risk has been shown in multiple candidate studies5–8. However, this strong 
association is limited to MSI+ cancers, and is weak or absent in un-stratified data sets. Several groups have 
investigated possible mechanisms by which this SNP may confer increased CRC risk, although the results are 
not straightforward. There is an association between the rs1800734 risk (A) allele and (i) DNA methylation at the 
MLH1 promoter in cancers9,10, and (ii) CpG island shore methylation in normal tissue11,12. There is also evidence 
that binding of the transcription factor TFAP4 (AP-4) is modified by rs180073413,14 in vitro and in vivo. However, 
Liu et al.13 detected no difference in MLH1 allele-specific expression as a result of TFAP4 allelic bias. Instead, they 
showed an effect on the expression of the gene encoding the protein kinase DCLK3 and long-range chromatin 
interactions between rs1800734 and the DCLK3 promoter.
Here we confirm the association of rs1800734 with CRC risk in our own MSI+ data set, confirm its absence 
in MSS cancers and perform a meta-analysis with other publically available MSI+ datasets. We then describe 
a comprehensive study which confirms MLH1 as the target gene, and investigate the relationship between the 
rs1800734 allele, MLH1 promoter methylation and, importantly MLH1 mRNA expression in normal tissue and 
the pathway to colon cancer. To add to this correlative data, we demonstrate the causal role of methylation by 
dynamically altering MLH1 promoter methylation levels, and showing that methylation loss and gain is modified 
by the rs1800734 allele with downstream effects on mRNA expression and TFAP4 binding.
Results
rs1800734 is strongly associated with MSI+ positive CRC risk but not MSS cancers. The MLH1 
promoter SNP rs1800734 has been assessed as a candidate for CRC susceptibility in a number of MSI+ colorectal 
cancer data sets. We confirmed these results in our own MSI+ data set from the VICTOR and QUASAR2 CRC 
clinical trials (n = 170, Supplementary Table 1 OR = 1.95, 95%CI 1.50–2.55, p = 8.04 × 10−7). A meta-analysis of 
these data and 5 other data sets showed a highly significant association with CRC risk (OR = 1.50; 95% CI 1.34, 
1.66; Pmeta < 10−10; 6640 cases and 8645 controls5–8. If an allelic model is used AG heterozygotes are at ~1.3-fold 
increased risk of MSI+ CRC compared with GG homozygotes, and AA homozygotes at ~2.6-fold raised risk. 
These are the largest effect sizes of any known common CRC predisposition SNP. Notably, MSI negative CRC 
cases show no significant association (OR = 1.03, p = 0.133) strongly suggesting that the SNP plays a mechanistic 
role in the silencing of MLH1 during MSI+ cancer development.
The risk allele of rs1800734 is associated with allele-specific CpG island shore methylation in 
normal bowel tissue, but no consistent bias in MLH1 mRNA expression. We devised a compre-
hensive analysis of the relationship between rs1800734 genotype, MLH1 promoter methylation and MLH1 mRNA 
expression in normal bowel (Supplementary Table 2), MSI+ CRCs (Supplementary Table 3) and sessile serrated 
adenomas (SSAs, Supplementary Table 4)), the putative precursor lesion of MSI+ CRCs (Fig. 1a). Figure 1b 
shows the methylation across the MLH1 CpG island and shore in normal colon tissue determined by next gener-
ation sequencing (NGS) of amplicons of bisulphite-treated DNA. As expected, there was little or no methylation 
close to rs1800734 or in Deng region C (used for clinical evaluation of MLH1 promoter methylation in MSI+ 
cancers15) in any of the samples. There were, however, increasing levels of methylation towards the upstream CpG 
island shore and interestingly these were higher in low-risk GG homozygotes than in AG heterozygotes (n = 39, 
Supplementary Table 2 (labelled green), p = 0.011, ANOVA; insufficient AA samples were present for statistical 
analysis). Though contrary to expectations, this is in agreement with previous studies12. We therefore wished to 
investigate any possible impact of this differential methylation on mRNA expression in our normal tissue sam-
ples. Since, we expected any allele-specific effects to be relatively small in this normal tissue without significant 
methylation in Deng region C, we developed a sensitive technique able to detect small allelic biases in cDNA by 
using next generation sequencing. We used heterozygous patients to carry out allele-specific expression analysis 
by reverse transcriptase PCR across the 5′ UTR region containing rs1800734 followed by sequencing and allelic 
counting. This allowed us to measure the ratio of risk to protective allele within an individual patient sample. 
Figure 1b shows that the mRNA allelic ratio was variable, but did not differ significantly from 1:1 in these patients 
(n = 41, Supplementary Table 2 (labelled yellow) p = 0.1495 T-Test). The allelic ratio from genomic DNA (1:1) 
was shown to be 1:1 confirming the absence of copy number changes or PCR amplification bias. We also found 
no eQTL at rs1800734 in our sample set (Fernandez-Rozadilla unpublished) or in publically available GTEx 
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Figure 1. Allele specific methylation and expression of rs1800734 in the 5′ UTR of MLH1 is seen in 
MSI+ cancers and SSAs but not in normal bowel. (a) Map of the promoter regions of MLH1 showing the 
chromosomal location of rs1800734 (chr3:37034946 (hg19), black triangle and dotted line, hg19), exon 1 of 
MLH1, the gene EPM2AIP, Deng region C (yellow line) and regions assessed for overall methylation (long 
green), allele specific methylation (short green) and allele specific expression (orange). (b) Normal bowel: 
(left panel) scatter plot showing total methylation levels across all CpGs in the region with samples grouped 
by genotype. Loess curves for each genotype are shown with standard error shaded in grey; (right panel) 
boxplot showing MLH1 allelic mRNA expression ratio (A/G) in heterozygous samples comparing cDNA with 
genomic DNA. (c) Cancer: (left panel) scatter plot showing allele specific methylation levels across CpGs close 
to rs1800734 with samples grouped by allele. Loess curves for each allele are shown with standard error shaded 
in grey; (right panel) boxplot showing total MLH1 mRNA levels in all samples grouped by genotype. (d) Loss 
of MLH1 protein in MSI CRC (ID Number 15-I-25344 in Supplementary Table 3): Immunohistochemistry was 
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intestinal data sets (GTex Data Portal), which taken together suggest that rs1800734 does not exert any effect on 
mRNA expression in normal colon tissue despite influencing DNA methylation at the CpG island shore.
in MSi+ cancers the risk (A) allele of rs1800734 is associated with increased methylation and 
lower levels of expression. Similar analyses were carried out in tumours from MSI+ cancer patients (col-
lected at the Department of Pathology of ASST dei Sette Laghi, University of Insubria) with loss of MLH1 protein 
expression (Fig. 1d, Supplementary Table 3). Methylation levels as determined by MS-MLPA were variable but 
still significantly higher in AA and AG patients than GG patients across the CpG island (n = 35, p = 0.0002, 
ANOVA, Supplementary Fig. 1). We interrogated these samples further to determine if these differences were 
specifically due to increased levels on the A allele in heterozygous patients, again using bisulphite-treated DNA 
amplified by PCR, followed by 250 bp paired-end reads and MiSeq NGS (Illumina) to allow phasing of rs1800734 
allele with methylation in region C. Despite variable levels of methylation between patients, in the 12 heterozy-
gous patients, 15 samples in total, we found methylation on the A allele was significantly greater than the G allele 
(Fig. 1c, n = 15 Supplementary Table 3 (rs1800734 genotype AG), p = 0.0322, ANOVA). In patients of all 3 gen-
otypes, mRNA expression levels also varied significantly with genotype (Fig. 1c, n = 35, Supplementary Table 3, 
p = 0.0001, ANOVA). Expression levels were significantly correlated with methylation levels (p = 1.67 × 10−5, 
Pearson), suggesting a causal relationship.
We wished to validate our findings on a 2nd larger dataset with a broader demographic. We therefore carried 
out a similar analysis on colorectal cancer with matched normal data from The Cancer Genome Atlas (TCGA 
COADREAD, http://cancergenome.nih.gov/). We found that methylation in region C and at rs1800734 was sig-
nificantly higher in tumours with AA and AG genotypes (Supplementary Fig. 2a, n = 432, p = 0.000133 ANOVA). 
When stratified by MSI status the MSI+ tumours alone still showed a genotype specific significant difference in 
methylation levels (Fig. 2, n = 157, p = 0.00115), however MSS tumours showed no allele specific differences 
(Supplementary Fig. 2b, n = 275, p = 0.627). Interestingly there was also some difference in methylation in nor-
mal tissue samples taken from cancer patients (Supplementary Fig. 2c, n = 31, p = 0.0071), which differed from 
our findings in normal tissue taken from control patients. Analysis of mRNA expression levels on the same data 
sets showed that these also varied significantly with genotype in all tumour samples (Supplementary Fig. 2d, 
n = 432, p = 0.00153, ANOVA). When stratified by MSI status the MSI+ tumour samples alone showed a highly 
significant difference between the genotypes (Fig. 2, n = 157, p = 0.0006) whereas the MSS tumour samples 
showed no effect of genotype on expression (Supplementary Fig. 2e, n = 275, p = 0.627). Normal tissue showed 
no variation at all (Supplementary Fig. 2f, n = 31, p = 0.99). As in our MSI+ cancer data set, expression and 
methylation showed a highly significant correlation (p-value < 10−15, Pearson). Early lesions in the pathway to 
cancer could represent intermediate stages in the process of MLH1 silencing. Sessile serrated adenomas (SSAs) 
are known precursors of BRAF-mutant MSI+ CRCs16. SSAs that develop dysplasia progress rapidly to cancer and 
approximately 75% of these have methylated MLH1 promoters and silencing17. Fennel et al.18 have shown that the 
rs1800734 risk (A) allele is associated with a dosage dependent increase in methylation in SSAs with dysplasia. 
The AA genotype was also associated with protein loss as measured by immunohistochemistry. We hypothe-
sised that SSAs would show allele-specific expression at the mRNA level, so we investigated allele-specific MLH1 
mRNA expression and methylation in a small set of fresh-frozen rs1800734-heterozygous SSAs with BRAFV600E 
mutations (n = 5, Supplementary Table 4, Supplementary Fig. 3). Our sample set lacked power to demonstrate 
allele specific methylation (p = 0.120 T-test, Supplementary Fig. 3a). However the gradient of methylation across 
the region is clearly visible with a significant difference between region C (chr3: 37034600-37034800) and the 
region encompassing rs1800734 (chr3: 37034900-37035100, p < 10−5, T-test), possibly indicating that hyper-
methylation is spreading from the CpG island shore across region C towards rs1800734. The intermediate levels 
of methylation present in our SSAs are already sufficient to cause a difference in allelic mRNA expression levels 
(p = 0.039, T-Test, Supplementary Fig. 3b) Taken together with the findings of Fennel et al.18, the combined data 
suggest that rs1800734 genotype can influence DNA methylation and mRNA transcription at an early stage in the 
serrated pathway to colorectal cancer.
Removal of DNA methylation causes de-repression of MLH1 transcription with an allele-specific 
bias. The MSI+ CRC cell line CO-115 (heterozygous for rs1800734 (A/G), BRAFV600E) has very high lev-
els of methylation at all CpGs analysed in the MLH1 promoter (Fig. 3a, mean = 91%) and expression of MLH1 
is undetectable by Q-PCR (Fig. 3b). Hypermethylation is observed on both the A and G alleles although some 
CpGs show lower levels on the G allele. We hypothesized that the untreated cells represented the endpoint state, 
after promoter methylation has been completed. We wished to take a dynamic approach to determine if DNA 
methylation is the primary and causal event leading to MLH1 transcriptional silencing and to observe how the 
rs1800734 allele affects the rate of loss and gain of methylation. 5-azacytidine and 5-aza-2′-deoxycytidine are 
chemical analogues of cytosine and inhibitors of DNA methylation. They cause a global loss of methylation when 
used to treat cell lines19. When treated with 5 μM 5-aza-2′-deoxycytidine (AzaC) for 48 hours, we saw a reduction 
in DNA methylation at all CpGs (mean methylation = 50%, p < 1 × 10−15 ANOVA), which gradually increased 
again over 11 days (Fig. 3a). Interestingly at all stages of the experiment we observed significantly higher levels of 
carried out using Ventana monoclonal antibodies anti-MLH1 (clone M1) on VENTANA BenchMark ULTRA 
platform. A case was considered immuno-negative (right panel; 200X, scale bar = 100 µm) when all of the 
tumour cell nuclei or a defined cluster of tumor cells failed to react with the specific antibody, with an intact 
nuclear staining of mixed non-tumor cells. Normal residual colorectal mucosa of the same sample was MLH1 
immunopositive (left panel; 200X, scale bar = 100 µm).
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methylation on the risk (A) allele (p = 0.0137, two-way ANOVA), with the A both taking longer to lose its meth-
ylation and regaining it more quickly. The loss of MLH1 methylation was accompanied by re-expression of MLH1 
mRNA, peaking at 4 days post-AzaC treatment (Fig. 3b; p = 0.007, ANOVA) and then starting to reduce by day 
11 post-treatment. Again, there were allele-specific differences at each stage, with the risk (A) allele expressed 
at lower levels than the protective (G). Re-expression of MLH1 to similar levels was also seen in a second MSI+ 
CRC cell line, SW48, following 5AzaC-induced loss of methylation (Supplementary Fig. 4).
TFAP4 binding at rs1800734 is allele-specific. Liu et al.13 demonstrated in a cell-free system that the 
transcription factor TFAP4 binds in vitro to the protective (G) allele of rs1800734 with higher affinity than to 
the risk (A) allele. We hypothesized that preferential TFAP4 binding on the G allele may give some protective 
effect from de novo DNA methylation machinery. We therefore confirmed that in the heterozygous MSS cell 
line COLO320, TFAP4 binds strongly and in a localized fashion to the region containing rs1800734 (Fig. 4a). In 
addition, we showed a highly significant allele-specific bias in binding towards the G allele (Fig. 4b; p = 0.00295, 
t-test). We have also showed the TFAP4 binding location and allelic bias in a second heterozygous MSS cell line, 
CACO2 (Supplementary Fig. 5a,b; p = 0.0145, t-test). However, the MSI+ CO-115 cells in their methylated state 
had no detectable TFAP4 binding (Fig. 4c left panel) at rs1800734. Strikingly, after AzaC treatment to remove 
methylation, we observed strong TFAP4 binding in CO-115 at the rs1800734 in all post-treatment time-points 
(Fig. 4c middle and right panels), reflecting the methylation and MLH1 expression changes seen in Fig. 3. We 
additionally discounted any significance of rs1800734 genotype on the expression of DCLK3 280 kb upstream of 
MLH1, contrary to previous reports13 (Supplementary Fig. 6).
Discussion
We have confirmed that the SNP rs1800734 in the promoter of MLH1 is associated with the risk of sporadic MSI+ 
CRC, but has no effect on MSS risk. This strong influence on the mismatch repair pathway and the repressive 
effect of the rs1800734 risk allele on transcription of the mismatch repair pathway protein, MLH1, confirms this 
as the target gene. Our results demonstrate that the risk (A) rs1800734 allele has no measurable repressive effect 
on MLH1 in normal bowel tissues, even using highly sensitive techniques, and in fact associates with reduced 
DNA methylation at the upstream CpG island shore, in line with previous observations12. However, significant 
allele specific effects are seen on both methylation and mRNA expression in MSI+ cancers in our own and TCGA 
data sets. As expected, the risk (A) allele leads to significantly higher methylation levels and this strongly corre-
lates with lower mRNA expression. The data of Fennell et al.18 and our small set of SSAs indicate that the allele 
methylation and expression bias probably arise very close together, during the serrated pathway.
We have also clearly demonstrated that DNA methylation is necessary for MLH1 transcriptional silencing by 
treating with AzaC, removing methylation and demonstrating re-expression of MLH1 in MSI+ cells. This result 
implies that methylation is indeed the primary cause of MLH1 silencing in sporadic MSI+ cancers. Interestingly, 
even in this engineered situation the risk (A) allele is more prone to acquire methylation and its mRNA is 
re-expressed at lower levels. Thus it is likely that the mechanism by which rs1800734 mediates cancer risk is via 
methylation acquisition. The reason the A allele is more readily methylated could be due to the lack of binding of 
the TFAP4 transcription factor as shown by Liu et al.13. We confirm their result that there is indeed a strong bias 
in TFAP4 binding in unmethylated CRC cells and that this binding is dependent on promoter demethylation post 
AzaC treatment in MSI+ cells.
Figure 2. Allele specific methylation and expression of rs1800734 in the 5′ UTR of MLH1 in MSI+ colorectal 
cancers from The Cancer Genome Atlas (left panel) scatter plot showing differential methylation levels across 
CpGs close to rs1800734 with samples grouped by genotype. Loess curves for each genotype are shown with 
standard error shaded in grey. rs1800734 (chr3:37034946 (hg19)), is shown by the black triangle; (right panel) 
boxplot showing total MLH1 mRNA levels in all samples grouped by genotype.
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It is unlikely that TFAP4 is the only transcription factor binding across rs1800734 and publically available 
genome wide ChIP-seq experiments show multiple proteins binding in the region (ENCODE, UCSC). Indeed, 
TFAP4 has been shown to belong to a class of enhancer binding factors that are important for co-factor recruit-
ment and activation20. This suggests that it could be a major factor in determining protein binding and potentially 
chromatin landscape across the region. The fact that TFAP4 also binds allele specifically to another disease asso-
ciated SNP (rs12722522, Type 1 diabetes21) suggests it might play a more generalised role in a subset of SNP trait 
associations, acting to recruit activating factors in an allele specific manner. Thus, as our data suggest, the effect 
of TFAP4 on de novo methylation of the MLH1 promoter is unlikely to be direct and therefore may only offer 
partial protection such that the rs1800734 protective (G) allele can still acquire methylation but at a slower rate or 
at lower levels than the risk (A) allele.
Liu et al.13 suggest that allele specific TFAP4 binding at rs1800734 may exert an effect on the cancer pathway 
via long range interactions with the promoter of the DCLK3 gene, causing enhanced expression of genes related 
to epithelial-to-mesenchymal transition. However we were unable to corroborate this finding. We failed to detect 
significant DCLK3 expression in either our MSS or MSI+ cell lines using sensitive Q-PCR based techniques. We 
have clearly demonstrated that rs1800734 is only associated with an increased risk of MSI+ cancers, ie those with 
a dysfunctional MMR pathway, and only modifies methylation in these and not in MSS cancers. Thus, it seems 
unlikely that a gene with no known role in MMR plays the primary or causative role in rs1800734 associated 
cancer risk.
Our data, taken together with other studies described above, support the prevailing hypothesis that MLH1 
repression is the main mechanism by which rs1800734 confers cancer risk. Since the majority of our MSI+ 
cancers (23/35) and all our SSA samples also carry a BRAFV600E mutation we suggest it is likely that rs1800734 
influences the acquisition of methylation via the BRAF/MAFG pathway described by Feng et al.4. Figure 4d repre-
sents our proposed model in which TFAP4, with co-factors binds within the promoter region on the G protective 
Figure 3. Allele specific analysis of MLH1 demethylation and derepression after AzaC treatment of CO-
115 cells. (a) Line-graphs showing percentage methylation levels at individual CpGs in the rs1800734 region 
grouped by allele. Each panel shows a control or time-point post AzaC treatment. The position of rs1800734 is 
marked (chr3:37034946 (hg19), black triangle). (b) Barchart showing total MLH1 mRNA expression and the 
allelic components of this expression in control cells and time-points post AzaC treatment. Error bars show the 
standard error of the mean of replicates. Asterisks denote significant (*p < 0.05) or highly significant (*p < 0.01) 
increases in expression in AzaC treated cells compared with untreated.
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Figure 4. Allele specific binding of TFAP4 in the rs1800734 region in COLO320 (MSS) cells and induction in 
TFAP4 binding after AzaC treatment of CO-115 (MSI) cells. (a) Chromatin immunoprecipitation (ChIP) with 
TFAP4 in COLO320 cells shows an enrichment at rs1800734 (chr3:37034946 (hg19), black triangle). (b) Graph 
showing allele specific analysis of ChIP input and TFAP4 pull down with the input showing an unbiased A/G 
allelic ration and TFAP pull down showing a strong bias towards the G allele. Asterisks denote highly significant 
(p < 0.01) differences between alleles. (c) Linegraphs showing no TFAP4 binding in untreated CO-115 cells with 
enrichment seen at 4 days and 11 days post AzaC treatment. (d) Cartoon showing proposed mechanism by which 
rs1800734 influences MLH1 expression. (Upper Panel) The protective allele (G, green triangle, upper panel) binds 
TFAP4 (yellow) which protects the promoter (black arrow) from BRAF and MAFG (blue) directed methylation 
and/or methylation spreading from the CpG island shore. The grey shaded area represents methylation levels 
across the region. (Lower Panel). The risk allele (A, red inverted triangle) does not bind TFAP4 allowing MAFG 
and cofactors to mediate DNMT3B methylation in the promoter region causing transcriptional repression.
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allele. This restricts the access of the BRAF activated MAFG complex and consequently reduces the spread of 
DNA methylation from the CpG island shore. On the A allele TFAP4 binding occurs less frequently or with lower 
affinity allowing MAFG access and methylation spreading.
While the functional role of rs1800734 in the pathways of CRC development is becoming clearer, it is also 
interesting to note how readily the accumulation of MLH1 promoter methylation could be reversed resulting in 
re-expression of MLH1. The importance of MLH1 promoter methylation in other cancer types is less well under-
stood however it is frequently found in endometrial22, and gastric23) cancers, as well as lung24, bladder25, and some 
haematological malignancies26. Drugs such as Azacitidine that inhibit DNA methylation are already approved for 
the treatment of some cancers. However with the advent of CRISPR technology, more precise demethylation is 
now possible27 and could be harnessed in the design of future therapies.
Methods
Patient samples. A summary of all patient sample sets used in this study is given in Supplementary Fig. 7. 
Patient samples for genetic studies were as reported in Allan et al., Campbell et al., Raptis et al., Whiffin et al.5–8,28 
plus our own dataset using clinical trial samples (QUASAR229 and VICTOR30,31). All patients were genotyped on 
Illumina tagSNP or custom arrays and quality control was performed as previously described.
Normal colorectal biopsies from 317 individuals of white UK origin undergoing colonoscopy in Oxford 
as previously reported32, were used for allele specific analysis of methylation and MLH1 mRNA expression. 
Formalin Fixed Paraffin Embedded (FFPE) CRC MSI+ tumours for analysis of methylation, expression and 
rs1800734 were collected at the Department of Pathology of ASST dei Sette Laghi- University of Insubria. 35 
consecutive sporadic CRCs showing MSI and MLH1/PMS2 immunohistochemical loss were selected33. All CRCs 
were histologically reviewed according to the World Health Organization (WHO) classification of tumors of the 
digestive system34 and the TNM staging system35 These patients were 20 females and 15 males with a mean age 
at CRC diagnosis of 77 years (range: 55–88 years). Thirty-two neoplasms arose in right colon, one in descending 
colon and the remaining two cases in sigmoid colon. Sessile serrated adenomas were collected fresh and frozen 
following endoscopic resection.
Ethical review. Collection of blood and tissue samples and clinico-pathological information from patients 
and controls was undertaken with informed consent and ethical review board approval in accordance with the 
tenets of the Declaration of Helsinki.
Victor and Ethical approval for the QUASAR study was obtained from the West Midlands Research Ethics 
Committee (Edgbaston, Birmingham, UK; REC reference: 04/MRE/11/18). The VICTOR trial was reviewed by 
the Cancer Research Campaign, the Multicenter Research Ethics Committee, and research ethics committees 
at participating centers. Ethical approval for the normal patient samples was obtained from the Oxfordshire 
Research Ethics Committee A (REC 10/H0604/72). The formalin fixed paraffin embedded (FFPE) CRC MSI+ 
tumours sample study was approved by the Ethics Committee of Ospedale di Circolo di Varese (No. 0037028). 
The sessile serrated adenomas was approved by Oxford Radcliffe Biobank ethics committee (09/H0606/5 + 5 ORB 
biobank, 13/SL/Precursor-lesions).
SNP genotyping. Patient samples and cell lines were genotyped for rs1800734 using KASPTM technology 
according to the manufacturer’s instructions (LGC). Primers are listed in Supplementary Table 4.
Analysis of methylation. DNA was extracted from fresh cells or tissue using the DNeasy kit (QIAGEN) 
or from FFPE tissue using the High Pure FFPET DNA Isolation Kit (Roche). Bisulphite conversion of DNA was 
carried out using the EZ DNA methylation kit (Zymo Research) according to the manufacturer’s instructions. 
Converted DNA was amplified with Pyromark PCR kit (Qiagen) using CpG free primers with Illumina spe-
cific sequence tags to ensure unbiased amplification of methylated and unmethylated template (Supplementary 
Table 4). Amplicons from each patient were barcoded together using a custom set of index tags and primers36. Up 
to 96 samples were sequenced using 250 bp paired end sequencing on a MiSeq (Illumina) according to the man-
ufacturer’s instructions. MiSeq output was demultiplexed and FASTQ files generated (Basespace, Illumina). The 
sequences were quality assessed, and trimmed (FastQC and TrimGalore, Babraham Bioinformatics) then aligned 
and the methylation called (Bismark, Babraham Bioinformatics).
MLH1 Methylation analysis on FFPE CRCs was performed in two replicates for each sample by MS-MLPA 
using the SALSA MS-MLPA ME011-Mismatch Repair genes kit (version B3) (MRC-Holland, Amsterdam, The 
Netherlands). MS-MLPA was performed according to the manufacturer’s instructions and data analysis was car-
ried out with Coffalyser software v.8 (MRC-Holland).
Analysis of mRNA. RNA was extracted from fresh cells or tissue using the RNeasy kit (QIAGEN) or 
from FFPE tissue using the High Pure FFPET RNA Isolation Kit (Roche) and cDNA was generated (High 
Capacity cDNA Reverse TRAnscription Kit, Applied Biosystems) according to the manufacturer’s instructions. 
Gene expression was quantified and normalized using Taqman gene expression ready mixed assays (Applied 
Biosystems, Thermofisher). Allele specific MLH1 expression was assessed by amplification of cDNA using 
Illumina tagged primers (Supplementary Table 4) followed by NGS sequencing on a MiSeq (Illumina) as above. 
Trimmed FastQ sequences were aligned using bwa-mem and the rs1800734 variant called by Platypus37.
Cell culture. Cell lines were grown in Dulbecco Modified Eagles Medium or RPMI-1640 supplemented with 
10% fetal bovine serum and 1% penicillin streptyomycin (Sigma) at 37 °C in 5% CO2.
Chromatin Immunoprecipitation. Approximately 108 cells were crosslinked for 10 mins with 1% formal-
dehyde, neutralized with 125 mM glycine, washed with ice-cold PBS and scraped. After 2 further PBS washes, 
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cells were resuspended in lysis buffer, (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, protease inhibitors) sonicated 
using a Bioruptor (Diagenode) for 7–15 × 15 s cycles, centrifuged at max speed for 10 min at 4 °C and diluted 
1:10 in IP dilution buffer (1% triton-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris). Immunoprecipitation with 
approximately 5 ug of antibody (anti-TFAP4 Santa Cruz Biotechnology, sc-18593x) was carried out overnight at 
4 °C and then incubated for 4 hours with 50 ul of protein G Dynabeads (Invitrogen). Bead/antibody complexes 
were washed with TSEI (0.1% SDS, 1% TritonX-100, 2 mM EDTA, 20 mM Tris, 150 mM NaCl), TSEII (0.1% SDS, 
1% TritonX-100, 2 mM EDTA, 20 mM Tris, 500 mM NaCl), LiCl buffer (0.25LiCl, 1% NP-40, 1% deoxycholate, 
1 mM EDTA, 10 mM Tris-HCl) and TE according to standard protocols and eluted with 1% SDS, 0.1 M NaHCO3. 
1 ul of DNA was analyzed in duplicate or triplicate by SYBR green qPCR using PowerUp SYBR™ Green Master 
Mix (Thermofisher) and primers covering the MLH1 promoter region (Supplementary Table 5).
5-Aza-2′-deoxycytidine treatment. Adherent semiconfluent MSI+ cells in exponential growth were 
treated with 5 uM 5-Aza-2′-deoxycytidine in standard medium (AzaC, Sigma A3656) for 48 hours (with replen-
ishment of AzaC after 24 hours). AzaC was removed, cells washed with PBS, and then cultured in standard 
medium for 0, 4, 7 and 11 days. RNA and DNA were extracted simultaneously using the AllPrep kit (Qiagen) 
and MLH1 mRNA expression and promoter methylation assessed as described above. ChIP was carried out post 
AzaC treatment as described above.
Statistical analysis. SNP association studies were carried out using PLINK. All other statistical analysis was 
carried out using R unless otherwise stated. Graphs were drawn using core R functions, ggplot2 or excel.
Data Availability
The raw data is available on Mendeley at https://data.mendeley.com/datasets/hfpbctm7tg/draft?a=1c91e494-
cadc-4be0-a8ff-91d8736a28e7.
References
 1. Tougeron, D. et al. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the 
number and spectrum of frameshift mutations. Mod Pathol 22, 1186–1195, https://doi.org/10.1038/modpathol.2009.80 (2009).
 2. Le, D. T. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372, 2509–2520, https://doi.org/10.1056/
NEJMoa1500596 (2015).
 3. Jones, P. A. & Laird, P. W. Cancer epigenetics comes of age. Nat Genet 21, 163–167, https://doi.org/10.1038/5947 (1999).
 4. Fang, M., Ou, J., Hutchinson, L. & Green, M. R. The BRAF oncoprotein functions through the transcriptional repressor MAFG to 
mediate the CpG Island Methylator phenotype. Molecular cell 55, 904–915, https://doi.org/10.1016/j.molcel.2014.08.010 (2014).
 5. Allan, J. M. et al. MLH1 -93G > A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer 123, 
2456–2459, https://doi.org/10.1002/ijc.23770 (2008).
 6. Campbell, P. T. et al. Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions 
with lifestyle factors. Gut 58, 661–667, https://doi.org/10.1136/gut.2007.144220 (2009).
 7. Raptis, S. et al. MLH1 -93G > A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst 
99, 463–474, https://doi.org/10.1093/jnci/djk095 (2007).
 8. Whiffin, N. et al. MLH1-93G > A is a risk factor for MSI colorectal cancer. Carcinogenesis 32, 1157–1161, https://doi.org/10.1093/
carcin/bgr089 (2011).
 9. Mrkonjic, M. et al. Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSI-H 
colorectal cancer. PLoS One 5, e13314, https://doi.org/10.1371/journal.pone.0013314 (2010).
 10. Miyakura, Y., Tahara, M., Lefor, A. T., Yasuda, Y. & Sugano, K. Haplotype defined by the MLH1-93G/A polymorphism is associated 
with MLH1 promoter hypermethylation in sporadic colorectal cancers. BMC research notes 7, 835, https://doi.org/10.1186/1756-
0500-7-835 (2014).
 11. Savio, A. J. et al. MLH1 region polymorphisms show a significant association with CpG island shore methylation in a large cohort of 
healthy individuals. PLoS One 7, e51531, https://doi.org/10.1371/journal.pone.0051531 (2012).
 12. Savio, A. J. et al. The dynamic DNA methylation landscape of the mutL homolog 1 shore is altered by MLH1-93G > A polymorphism 
in normal tissues and colorectal cancer. Clin Epigenetics 9, 26, https://doi.org/10.1186/s13148-017-0326-6 (2017).
 13. Liu, N. Q. et al. The non-coding variant rs1800734 enhances DCLK3 expression through long-range interaction and promotes 
colorectal cancer progression. Nat Commun 8, 14418, https://doi.org/10.1038/ncomms14418 (2017).
 14. Savio, A. J. & Bapat, B. Modulation of transcription factor binding and epigenetic regulation of the MLH1 CpG island and shore by 
polymorphism rs1800734 in colorectal cancer. Epigenetics 12, 441–448, https://doi.org/10.1080/15592294.2017.1305527 (2017).
 15. Deng, G., Chen, A., Hong, J., Chae, H. S. & Kim, Y. S. Methylation of CpG in a small region of the hMLH1 promoter invariably 
correlates with the absence of gene expression. Cancer Res 59, 2029–2033 (1999).
 16. Sweetser, S., Jones, A., Smyrk, T. C. & Sinicrope, F. A. Sessile Serrated Polyps are Precursors of Colon Carcinomas With Deficient 
DNA Mismatch Repair. Clin Gastroenterol Hepatol 14, 1056–1059, https://doi.org/10.1016/j.cgh.2016.01.021 (2016).
 17. Bettington, M. et al. High prevalence of sessile serrated adenomas in contemporary outpatient colonoscopy practice. Intern Med J 
47, 318–323, https://doi.org/10.1111/imj.13329 (2017).
 18. Fennell, L. J. et al. MLH1-93 G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile 
serrated adenomas with BRAF(V600E) mutation. BMC Cancer 18, 35, https://doi.org/10.1186/s12885-017-3946-5 (2018).
 19. Mossman, D., Kim, K. T. & Scott, R. J. Demethylation by 5-aza-2′-deoxycytidine in colorectal cancer cells targets genomic DNA 
whilst promoter CpG island methylation persists. BMC Cancer 10, 366, https://doi.org/10.1186/1471-2407-10-366 (2010).
 20. Grossman, S. R. et al. Positional specificity of different transcription factor classes within enhancers. Proc Natl Acad Sci USA 115, 
E7222–E7230, https://doi.org/10.1073/pnas.1804663115 (2018).
 21. Butter, F. et al. Proteome-wide analysis of disease-associated SNPs that show allele-specific transcription factor binding. PLoS Genet 
8, e1002982, https://doi.org/10.1371/journal.pgen.1002982 (2012).
 22. Zighelboim, I. et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial 
carcinomas of the endometrioid type. J Clin Oncol 25, 2042–2048, https://doi.org/10.1200/JCO.2006.08.2107 (2007).
 23. Moura Lima, E. et al. DNA mismatch repair gene methylation in gastric cancer in individuals from northern Brazil. Biocell 32, 
237–243 (2008).
 24. Gomes, A. et al. Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell 
carcinomas of the lung. Rev Port Pneumol 20, 20–30, https://doi.org/10.1016/j.rppneu.2013.07.003 (2014).
1 0Scientific RepoRtS |         (2019) 9:13463  | https://doi.org/10.1038/s41598-019-49952-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
 25. Wojtczyk-Miaskowska, A., Presler, M., Michajlowski, J., Matuszewski, M. & Schlichtholz, B. Gene Expression, DNA Methylation and 
Prognostic Significance of DNA Repair Genes in Human Bladder Cancer. Cell Physiol Biochem 42, 2404–2417, https://doi.
org/10.1159/000480182 (2017).
 26. Matsushita, M. et al. Methylation of the MLH1 gene in hematological malignancies. Oncology reports 14, 191–194 (2005).
 27. Liu, X. S. et al. Editing DNA Methylation in the Mammalian Genome. Cell 167, 233–247 e217, https://doi.org/10.1016/j.
cell.2016.08.056 (2016).
 28. Whiffin, N. et al. Deciphering the genetic architecture of low-penetrance susceptibility to colorectal cancer. Hum Mol Genet 22, 
5075–5082, https://doi.org/10.1093/hmg/ddt357 (2013).
 29. Kerr, R. S. et al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): 
an open-label, randomised phase 3 trial. The Lancet. Oncology 17, 1543–1557, https://doi.org/10.1016/S1470-2045(16)30172-3 
(2016).
 30. Midgley, R. S. et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the 
VICTOR trial. J Clin Oncol 28, 4575–4580, https://doi.org/10.1200/JCO.2010.29.6244 (2010).
 31. Domingo, E. et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a 
retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol 1, 207–216, https://doi.org/10.1016/S2468-1253(16)30014-0 
(2016).
 32. Fernandez-Rozadilla, C. et al. Telomere length and genetics are independent colorectal tumour risk factors in an evaluation of 
biomarkers in normal bowel. Br J Cancer 118, 727–732, https://doi.org/10.1038/bjc.2017.486 (2018).
 33. Sahnane, N. et al. Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer. Clin Epigenetics 7, 131, https://doi.
org/10.1186/s13148-015-0165-2 (2015).
 34. Hamilton, S. Carcinoma of the colon and rectum. World health organization classification of tumors. Pathology and genetics of tumors 
of the digestive system, 105–119 (2000).
 35. Edge, S. B. The American Joint Committee for Cancer staging manual (Chicago: Springer, 2010).
 36. Lamble, S. et al. Improved workflows for high throughput library preparation using the transposome-based Nextera system. BMC 
Biotechnol 13, 104, https://doi.org/10.1186/1472-6750-13-104 (2013).
 37. Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing 
applications. Nat Genet 46, 912–918, https://doi.org/10.1038/ng.3036 (2014).
Acknowledgements
Funding was provided by a Medical Research Council New Investigator Research Grant (MR/P000738/1). Core 
funding to the Wellcome Trust Centre for Human Genetics was provided by the Wellcome Trust (090532/Z/09/Z). 
D.T., N.S. and D.F. were supported by the EPIGENOMICS FLAGSHIP PROJECT- EPIGEN (project number 
08934412) and by University of Insubria. M.T. and S.K. were funded by Ludwig Cancer Research. We thank R. 
Arnold, D., Church and M. Glaire for help with TCGA analysis, A. Goriely for help in developing the NGS based 
allele specific analysis and E. Domingo for assistance in gathering patient sample metadata.
Author Contributions
A.L. conceived the study. A.L., R.T., D.T., L.G.-S. N.S. and H.D. carried out the experiments. A.L., M.T., C.F-R., 
L.C., C.P. and I.T. analyzed the data. C.W., C.F.-R., T.M., S.L., D.F. and I.T., provided patient sample sets and 
data. M.T., L.C. and S.K. gave technical advice. A.L., D.F. and I.T. supervised the experiments. D.F. and I.T. gave 
conceptual advice. A.L. wrote the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-49952-x.
Competing Interests: The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
